apx001
Small moleculeexperimental
Clinical trial activity
12 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2016 (NCT02956499)
Timeline
Indications
Mechanism of action
- GPI-anchored wall transfer protein 1INHIBITOR
GWT1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- apx001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06961708 | Phase 1 | Apr 14, 2025 | Basilea Pharmaceutica, Department of Health and Human Services |
| NCT05582187 | Phase 1 | Oct 31, 2022 | Pfizer |
| NCT05491733 | Phase 1 | Mar 2, 2021 | Pfizer |
| NCT04240886 | Phase 2 | Jan 31, 2020 | Amplyx Pharmaceuticals |
| NCT04166669 | Phase 1 | Nov 12, 2019 | Amplyx Pharmaceuticals, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT04148287 | Phase 2 | Sep 15, 2019 | Amplyx Pharmaceuticals |
| NCT03604705 | Phase 2 | Aug 31, 2018 | Amplyx Pharmaceuticals |
| NCT04804059 | Phase 1 | Aug 17, 2018 | Pfizer |
| NCT03333005 | Phase 1 | Nov 27, 2017 | Amplyx Pharmaceuticals, University of Cologne |
| NCT02957929 | Phase 1 | Oct 1, 2016 | Amplyx Pharmaceuticals |
| NCT02956499 | Phase 1 | May 1, 2016 | Amplyx Pharmaceuticals |
| NCT06433128 | N/A | — | Basilea Pharmaceutica |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amplyx Pharmaceuticals | For profit | 7 | 7 | 2 | 2016 |
| Pfizer | For profit | 3 | 3 | 1 | 2018 |
| Basilea Pharmaceutica | For profit | 2 | 2 | 2 | 2025 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2025 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2019 |
| University of Cologne | Academic/Hospital | 1 | 0 | 1 | 2017 |
6 organizations
Page 1 / 1